A Phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of AZD6244 (hyd-sulfate) in combination with docetaxel, compared with docetaxel alone, in second-line patients with KRAS mutation-positive local advanced or metastatic non–small-cell lung cancer (Stage IIIB-IV).
Advanced or metastatic
non–small-cell lung cancer
To assess the efficacy in terms of progression-free survival of AZD6244 in combination with docetaxel compared with docetaxel alone
Progression-free survival
Overall survival, objective response rate, duration of response, change in tumor size at 12 weeks, alive and progression-free at 6 months, safety and tolerability, PK, investigate the use of plasma and serum as a potential source of CFDNA for the analysis of KRAS mutation status
Belgium, Brazil, Canada, Czech Republic, Denmark, France, Hungary, Italy, Mexico, Peru, Spain, United States
AZD6244 is an investigational compound. This information is intended for potential clinical investigators and other interested physicians who may wish to enroll patients in clinical trials.
To find available investigator site details, go to: www.clinicaltrials.gov
Download PDF (PDF— 
118 KB)